Loading patent…
AssigneeMillennium Pharmaceuticals, Inc.
InventorsWilliam James Cook, Rory A.J. Curtis, Frank Spaltmann
Estimating the term…
The present invention relates to a newly identified human agmatinase-like arginase, designated “25312”. The invention also relates to polynucleotides encoding the agmatinase-like arginase. The invention further relates to methods using the agmatinase-like polypeptides and polynucleotides as a target for diagnosis and treatment in disorders mediated by or related to the agmatinase-like arginase. The invention further relates to drug-screening methods using the polypeptides and polynucleotides to identify agonists and antagonists for diagnosis and treatment. The invention further encompasses agonists and antagonists based on the polypeptides and polynucleotides. The invention further relates to agonists and antagonists identified by drug screening methods with the polypeptides and polynucleotides as a target.
A method for identifying a compound which binds to a polypeptide which is at least 95% identical to the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4 or the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit Number PTA-1844 and wherein the polypeptide has an agmatinase activity, the method comprising:
A method for identifying a compound which binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:2, SEQ ID NO:4, the amino acid sequence encoded by the cDNA insert of the plasmid deposited with ATCC as Patent Deposit Number PTA-1844, or a fragment thereof comprising at least 15 contiguous amino acids, the method comprising:
Dependencies are inferred from the claim text.